sb 203580 has been researched along with tris(2-pyridylmethyl)amine in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (tris(2-pyridylmethyl)amine) | Trials (tris(2-pyridylmethyl)amine) | Recent Studies (post-2010) (tris(2-pyridylmethyl)amine) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 98 | 0 | 47 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hicks, MJ; Koitschev, A; Plinkert, PK; Simon, C; Simon, M; Vucelic, G; Zenner, HP | 1 |
1 other study(ies) available for sb 203580 and tris(2-pyridylmethyl)amine
| Article | Year |
|---|---|
The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation.
Topics: Base Sequence; Calcium-Calmodulin-Dependent Protein Kinases; Carcinogens; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Imidazoles; MAP Kinase Kinase 6; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Invasiveness; Neoplasms; p38 Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Protein Isoforms; Protein Structure, Tertiary; Proto-Oncogene Proteins c-jun; Pyridines; Signal Transduction; Terminal Repeat Sequences; Transcription Factor AP-1; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 2001 |